“… Van Seuningen et al (2000) investigated the 5′-flanking region and promoter activity of MUC5B in colon cancer cell lines and showed a cell-specific manner of MUC5B promoter activities, as MUC5B it is very active in mucus-secreting LS174T cells, whereas it is inactive in Cac-2 enterocytes and HT-29 undifferentiated cells. MUC5B upregulation has been found in human diseases, such as sinus mucosa polyps ( Wu et al, 2011 ), nasal polyps ( Amini et al, 2019 ), chronic obstructive pulmonary disease ( Hancock et al, 2018 ), and Helicobacter pylori-related gastropathy ( Zhang et al, 2018 ), suggesting the important role of MUC5B and its involvement in the pathogenesis of these diseases. In gastric and intestinal cancer cell lines, the expression of MUC5B was also found to be increased, such as HT-29 MTX cells ( Lesuffleur et al, 1995 ) and LS174T cells ( van Klinken et al, 1998 ).…”